ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
95.40 USD   +4.69%
05/16Berenberg Bank Adjusts Ascendis Pharma's Price Target to $168 From $192, Maintains Buy Rating
MT
05/12SECTOR UPDATE : Health Care Stocks Close Higher on Thursday
MT
05/12SECTOR UPDATE : Health Care Stocks Still Struggling for Direction Thursday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ascendis Pharma's Growth Hormone Drug TransCon hGH Gets EU Approval

01/13/2022 | 09:16am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASCENDIS PHARMA A/S 4.69% 95.4 Delayed Quote.-29.09%
HGH HOLDINGS LTD. 50.00% 0.018 Delayed Quote.28.57%
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
All news about ASCENDIS PHARMA A/S
05/16Berenberg Bank Adjusts Ascendis Pharma's Price Target to $168 From $192, Maintains Buy ..
MT
05/12SECTOR UPDATE : Health Care Stocks Close Higher on Thursday
MT
05/12SECTOR UPDATE : Health Care Stocks Still Struggling for Direction Thursday
MT
05/12SECTOR UPDATE : Health Care
MT
05/12TRANSCRIPT : Ascendis Pharma A/S Presents at Bank of America 2022 Healthcare Conference, M..
CI
05/12Credit Suisse Adjusts Ascendis Pharma's Price Target to $123 from $194, Keeps Outperfor..
MT
05/12Oppenheimer Adjusts Ascendis Pharma Price Target to $154 From $166, Maintains Outperfor..
MT
05/12Wedbush Adjusts Ascendis Pharma's Price Target to $127 From $163, Keeps Outperform Rati..
MT
05/12SVB Securities Adjusts Ascendis Pharma's Price Target to $174 from $193, Keeps Outperfo..
MT
05/12Citigroup Adjusts Ascendis Pharma's Price Target to $158 From $187, Reiterates Buy Rati..
MT
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 35,0 M 36,9 M 36,9 M
Net income 2022 -497 M -525 M -525 M
Net cash 2022 471 M 496 M 496 M
P/E ratio 2022 -10,2x
Yield 2022 -
Capitalization 5 046 M 5 324 M 5 324 M
EV / Sales 2022 131x
EV / Sales 2023 35,3x
Nbr of Employees 639
Free-Float 10,5%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 90,43 €
Average target price 143,12 €
Spread / Average Target 58,3%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-29.09%5 324
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612